Abstract 5084
Background
Teenage and young adult cancer services in England are centralised in 13 principal treatment centres (TYA PTC). We sought to evaluate whether caregivers of young people with cancer had fewer unmet information and support needs if cancer care was provided in a TYA PTC.
Methods
Participants in the cohort study of young people with cancer nominated their main carer to complete the BRIGHTLIGHT Carer Questionnaire. Questionnaires were completed six months after diagnosis. Comparisons were made according to where young people’s care was delivered: all, some or no care in a TYA PTC. Principal component analysis reduced the questionnaire to five dimensions, which were used as dependent variables in subsequent regression analysis.
Results
A total of 830 young people were part of the BRIGHTLIGHT Cohort, of which 514 (62%) caregivers returned a questionnaire. Four hundred and seventy-six responses out of 514 returned questionnaires (92%) could be linked to the location of young people’s care and were included in the analysis. The majority of caregivers were white (89.7%), middle aged (71.1%), married/cohabiting (78%) mothers (80.2%). The Adjusted analysis indicated that caregivers of young people who had all or some of their care in a TYA PTC had more satisfaction with support and also with services specifically provided for carers. Those who had some care in a TYA PTC had greater satisfaction with information but less opportunity to be involved in decisions.
Conclusions
Caregivers of young people who had no TYA PTC, i.e. treated solely in adult or children’s cancer units have the most unmet information and support needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
UCLH.
Funding
National Institute for Health Research (NIHR).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2108 - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3090 - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01
Presenter: Daniele Raggi
Session: Poster Display session 3
Resources:
Abstract
5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
Presenter: Albert Font
Session: Poster Display session 3
Resources:
Abstract
3206 - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
Presenter: Scott Tagawa
Session: Poster Display session 3
Resources:
Abstract
3110 - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
Presenter: Florian Roghmann
Session: Poster Display session 3
Resources:
Abstract
3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Presenter: Jean-Michel Lavoie
Session: Poster Display session 3
Resources:
Abstract
2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)
Presenter: Markus Eckstein
Session: Poster Display session 3
Resources:
Abstract
2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival
Presenter: Elise Nassif
Session: Poster Display session 3
Resources:
Abstract
2835 - Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Presenter: David Sarid
Session: Poster Display session 3
Resources:
Abstract
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract